Mentorship and Research in Bipolar and Substance Use Disorders

双相情感障碍和药物滥用障碍的指导和研究

• 批准号: 10740403
• 负责人: James Joseph Prisciandaro
• 金额: $ 21.5万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-01 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10740403
• 关键词: Academic Medical Centers; Area; Award; Behavioral Sciences; Bioinformatics; Biological Psychiatry; Biometry; Blood specimen; Brain; Clinical; Clinical Investigator; Data; Development; Diagnosis; Employment; Exposure to; Faculty; Funding; Future Generations; Genomics; Glutamates; Goals; Grant; Image; Individual; Investigation; Licensing; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Measurable; Medical; Mentors; Mentorship; Methodology; Methods; Mid-Career Clinical Scientist Award (K24); Monitor; National Institute on Alcohol Abuse and Alcoholism; Participant; Pharmaceutical Preparations; Phenotype; Postdoctoral Fellow; Productivity; Protons; Psychiatry; Psychologist; Research; Research Methodology; Resources; Science; Scientist; Source; South Carolina; Substance Use Disorder; Time; Training; United States National Institutes of Health; Universities; Wages; Work; addiction; alcohol cue; alcohol response; alcohol use disorder; biomedical imaging; career; cost; design; experience; gabapentin; gamma-Aminobutyric Acid; genetic variant; genomic variation; imaging study; improved; meetings; member; mid-career faculty; multimodality; neurobehavioral; neurochemistry; participant enrollment; patient oriented research; pharmacologic; programs; psychiatric genomics; psychogenetics; recruit; research study; skills; statistics; success

Dr. James J. Prisciandaro is a licensed Clinical Psychologist, Associate Professor in the Addiction Sciences Division of the Department of Psychiatry & Behavioral Sciences at the Medical University of South Carolina (MUSC), who is committed to making a measurable impact on our understanding and ability to treat individuals with bipolar (BD) and/or substance use disorders (SUD) through his program of patient-oriented research (POR). Dr. Prisciandaro has served as PI, Co-PI, or Co-I on 12 NIH-funded grant awards since joining MUSC in 2009, but his success in designing and executing NIH-funded research studies has come at a significant cost: his efforts to mentor new clinical investigators have been greatly limited by his employment within an academic medical center that is not able to provide faculty with protected time for mentoring or professional development. As a result of this lack of support, Dr. Prisciandaro has had to greatly limit the number of new clinical investigators that he has been able to mentor, and he has not been able to expand his methodological skillset since completing his K23 training 5-years ago. The proposed K24 award would allow Dr. Prisciandaro to fulfil his career goals by providing him with the protected time and supplementary funding needed to comprehensively train significantly more new clinical investigators and to develop and expand his methodological skills in MRI and statistics to include genomics. Towards this end, Dr. Prisciandaro has recruited several consultants and collaborators to help him create, execute, and monitor a comprehensive training plan, including longstanding collaborators within his fields of expertise (Drs. Richard Edden [MRI] and Michaela Hoffman [biostatistics]) along with three new consultants/collaborators, Drs. Ananda Amstadter (psychiatric genomics), Stefano Berto (genomics and bioinformatics), and Zhewu Wang (psychiatric genetics). With their guidance, Dr. Prisciandaro has proposed a research strategy to apply cutting-edge genomics methods to blood samples that he has collected from every participant enrolled in each of his NIH-funded studies to date, starting with those from his K23 study; a 2*2 factorial (BD*alcohol use disorder [AUD]), multimodal-MRI investigation of neurochemical (i.e., GABA and glutamate levels) and neurobehavioral overlap (i.e., activation to alcohol cues and response inhibition) between BD and AUD. Dr. Prisciandaro will devote the remainder of his effort to his current NIH-funded program of POR, focused on pharmacologically-manipulating intermediate MRI phenotypes of BD and/or SUD, which is tightly aligned with his career goals and a rich source for mentee training and productivity. As these pharmaco-imaging studies complete participant enrollment, Dr. Prisciandaro and his consultants/collaborators will apply to their data the proposed genomics methods, extended to include genetic variants underlying the mechanisms of action of the medications under investigation (e.g., gabapentin). He will involve mentees in all aspects of his POR, including all proposed genomics research. Together, these combined efforts will significantly advance both Dr. Prisciandaro's POR career as well as our understanding of and ability to treat individuals with BD+SUD.

Dr. James J. Prisciandaro是一位有执照的临床心理学家，成瘾科学副教授 南卡罗来纳州医科大学精神病学与行为科学系 （MUSC），致力于对我们治疗个人的理解和能力产生可衡量的影响 通过他的以患者为导向的研究（POR）计划，治疗双相情感障碍（BD）和/或物质使用障碍（SUD）。 博士自2009年加入MUSC以来，Prisciandaro已担任PI，Co-PI或Co-I的12个NIH资助的赠款奖项， 但他在设计和执行NIH资助的研究方面的成功是以巨大的代价为代价的： 指导新的临床研究者的努力受到了他在学术界的就业的极大限制。 医疗中心，是不能提供教师与保护的时间进行辅导或专业发展。 由于缺乏支持，Prisciandaro博士不得不大大限制新临床研究者的数量 他已经能够指导，他还没有能够扩大他的方法论技能，因为完成 他五年前接受过K23训练拟议的K24奖将使Prisciandaro博士能够通过以下方式实现其职业目标： 为他提供了全面训练所需的保护时间和补充资金， 更多新的临床研究者，并发展和扩大他在MRI和统计学方面的方法技能， 包括基因组学。为此，Prisciandaro博士招募了几位顾问和合作者来帮助 他创建、执行和监控一个全面的培训计划，包括他的长期合作者， 专业领域（Richard Edden博士[MRI]和Michaela霍夫曼[生物统计学]）沿着三个新的 顾问/合作者，Ananda Amstadter博士（精神病基因组学），Stefano Berto（基因组学和 生物信息学）和王哲武（精神病遗传学）。在他们的指导下，Prisciandaro博士提出了一个 研究策略，将尖端的基因组学方法应用于他从每个人身上收集的血液样本， 参与者参加了他迄今为止的每一项NIH资助的研究，从他的K23研究开始; 2*2 因子（BD* 酒精使用障碍[AUD]），神经化学的多模态MRI研究（即，GABA和 谷氨酸水平）和神经行为重叠（即，对酒精线索的激活和反应抑制）之间 BD和AUD。Prisciandaro博士将把剩余的精力投入到他目前由NIH资助的POR项目中， 专注于药理学操纵BD和/或SUD的中间MRI表型， 与他的职业目标一致，并为学员培训和生产力提供丰富的资源。因为这些药物成像 研究完成受试者入组后，Prisciandaro博士及其顾问/合作者将应用于他们的数据 拟议的基因组学方法，扩展到包括遗传变异的作用机制， 研究中的药物（例如，加巴喷丁）。他将让学员参与他的POR的各个方面， 包括所有拟议的基因组学研究。总之，这些共同的努力将显着推进博士。 Prisciandaro的POR职业生涯以及我们对BD+SUD患者的理解和治疗能力。